肿瘤细胞治疗研究
英文原题：The potential of γδ CAR and TRuC T cells: An unearthed treasure.
The potential of γδ CAR and TRuC T cells: An unearthed treasure.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来，表达嵌合抗原受体（CAR）的T细胞在治疗血液系统恶性肿瘤方面取得了成功。CAR将抗体的肿瘤抗原结合能力与T细胞受体（TCR）链及共刺激受体的信号传导功能相结合。尽管取得了成功，CAR-T 细胞仍面临局限性。可能的解决方案包括使用T细胞和新型嵌合受体，如TCR融合构建体（TRuCs）。值得注意的是，CAR-T 细胞在临床前和临床研究中正获得越来越多的关注，多项初步研究显示出有前景的安全性特征。本综述深入探讨了目前对CAR和TCR融合构建体T细胞的理解，探索了它们在癌症治疗中呈现的机遇与挑战。
Recent years have witnessed the success of T cells engineered to express chimeric antigen receptors (CARs) in treating haematological cancers. CARs combine the tumour antigen binding capability of antibodies with the signalling functions of the T-cell receptor (TCR) chain and co-stimulatory receptors. Despite the success, CAR T cells face limitations. Possible solutions would be the use of T cells and new chimeric receptors, such as TCR fusion constructs (TRuCs).
Notably, CAR T cells are gaining traction in pre-clinical and clinical studies, demonstrating a promising safety profile in several pilot studies. This review delves into the current understanding of CAR and TCR fusion construct T cells, exploring the opportunities and challenges they present for cancer treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
